Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

So, AstraZeneca's revenue reached $13.59 billion ... camizestrant, rilvegostomig, and tozorakimab, its EBIT margin reached 27.7% in Q1 2025, up about 3.4% year-over-year. I'll continue with ...

Credit: crystal light/Shutterstock. On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, ...

AstraZeneca's first-in-class rescue inhaler ... Meanwhile, AZ is working to expand Fasenra, Tezspire and IL-33 candidate tozorakimab into COPD. The company believes there is value in bringing ...

WILMINGTON, Del., May 13, 2025--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

inhibitor tozorakimab (AstraZeneca). Additionally, the CD40/CD40L axis may introduce therapeutic alternatives for systemic diseases, including dazodalibep (Amgen) for Sjögren’s syndrome and ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of ...

Tozorakimab received FDA Fast Track Designation ... Alexion and Chief Strategy Officer, AstraZeneca Thank you, Sharon, and ...

AstraZeneca (NASDAQ:AZN ... including camizestrant, baxdrostat, tozorakimab, and eneboparatide. At the same time, when forecasting the growth rates of the company's revenue and operating income ...

Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 ...